

SAMARITAN PHARMACEUTICALS INC  
Form 8-K  
October 16, 2007

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

October 16, 2007

**Samaritan Pharmaceuticals**

(Exact name of registrant as specified in its charter)

Nevada

001-32287

88-0431538

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

101 Convention Center , Suite 310, Las Vegas,  
Nevada

89109

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

702-735-7001

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 1.01 Entry into a Material Definitive Agreement.**

Samaritan Pharmaceuticals Inc., under a March 9, 2007 agreement with Pharmaplaz, Ltd., a private Irish healthcare company, where Samaritan receives \$10 million non-refundable upfront money in two payments to develop and commercialize HIV entry inhibitor drug SP-01A, they have received the second upfront payment of \$8.6M.

Under the terms of the agreement, Samaritan received \$1.4M of the \$10 million upfront payment upon the signing of the agreement. Pharmaplaz takes financial responsibility for the future development of SP-01A and upon successful commercialization; Samaritan and Pharmaplaz will share 50-50 in SP-01A's revenue royalty stream.

**Item 7.01 Regulation FD Disclosure.**

On Oct. 16, 2007, Samaritan Pharmaceuticals Inc. announced that, under a March 9, 2007 agreement with Pharmaplaz, Ltd., a private Irish healthcare company, where Samaritan receives \$10 million non-refundable upfront money in two payments to develop and commercialize HIV entry inhibitor drug SP-01A, they have received the second upfront payment of \$8.6M.

Under the terms of the agreement, Samaritan received \$1.4M of the \$10 million upfront payment upon the signing of the agreement. Pharmaplaz takes financial responsibility for the future development of SP-01A and upon successful commercialization; Samaritan and Pharmaplaz will share 50-50 in SP-01A's revenue royalty stream.

**Item 9.01 Financial Statements and Exhibits.**

d) Exhibits.

99.1 Press Release dated October 16, 2007

This information contained in this report contains forward-looking statements which are subject to uncertainties that could cause actual future events and results of the Company to differ materially from those expressed in the forward-looking statements. These forward-looking statements are based on estimates, projections, beliefs, and assumptions that the Company believes are reasonable but are not guarantees of future events and results. Actual future events and results of the Company may differ materially from those expressed in these forward-looking statements. There can be no assurance that any forward-looking statements will be realized. Factors that may cause actual results to differ materially from those contemplated by such forward looking statements include, among others, the risks described in the Company's most recent Annual Report on Form 10-K and the Company's other reports filed with the SEC. All such forward-looking statements speak only as of the date hereof. Although the Company believes the expectations reflected in the forward-looking statements at the time they are made are reasonable, the Company

cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as it believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.

You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information contained herein as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the Company's filings with the SEC at [www.sec.gov](http://www.sec.gov), many of which are beyond the Company's control, that may cause actual results to differ materially from the views, beliefs and estimates expressed herein.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Samaritan Pharmaceuticals

*October 16, 2007*

By: *Eugene Boyle*

---

*Name: Eugene Boyle*

*Title: CFO*

---

**Top of the Form**

Exhibit Index

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press Release dated October 16, 2007